AKT1 and breast carcinoma: Importantly, we demonstrate that silencing SEMA3C inhibits the MAPK and AKT signaling pathways, promotes apoptosis, and suppresses the growth of both tamoxifen-sensitive and resistant ER+ breast cancer cells.